Clinical Study
Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study
Table 4
Patients’ outcome.
| | Group characteristics | First group (1) | Second group (2) | | Standard GVHD prophylaxis () | Standard GVHD prophylaxis + MMSC () |
| | Death at +100 days, n, % | 1 (10%) | 0 | | aGVHD (II–IV grade), n, % | 6 (33.3%) | 1 (5.3%) | | cGVHD (lim + ext), n, % | 6/17 (35.3%) | 5/18 (27.8%) | | Relapse rate, n, % | 5/18 (27.7%) | 4/19 (21.1%) | | Alive, n, % | 14 (77.7%) | 18 (94.7%) |
|
|
cGVHD form: lim-limited, ext-extensive.
|
